Plain-English translation of NCT07257640 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing IL-5 CAR-T cell therapy, a new treatment that uses your own immune cells engineered to recognize and fight eosinophilic leukemia. Doctors will modify your white blood cells in the laboratory to make them better able to detect and destroy the cancer cells. The study will evaluate whether this treatment is safe and how well it works for patients whose leukemia has not responded to standard medicines or has returned.
Eosinophilic leukemia can be very difficult to treat when it becomes resistant to standard therapies or comes back after initial treatment. This trial exists to see whether this new therapy, which uses engineered immune cells, might offer hope to patients who have limited options left.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will first receive conditioning treatment to prepare your body for the new cells. Then doctors will collect some of your white blood cells, send them to a laboratory where they will be engineered with special receptors, and infuse the modified cells back into your bloodstream. After the infusion, you will have regular appointments to be monitored closely for any side effects and to measure how well the treatment is working. The study will track your health and disease response over time.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
China
Phase
Safety & dosing
Sponsor
Zhejiang University
Enrollment target
~20 participants
Started
November 2025
Primary completion
November 2028
Age range
18 Years and older
Last updated on clinicaltrials.gov in December 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Songmin Ying, MD
First Affiliated Hospital of Zhejiang University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.